Herpes simplex virus-1（HSV-1）感染可以对个体造成重大伤害，包括失明、先天缺陷、生殖器疱疹甚至癌症等，没有明确的治愈方法。因此，寻找新的治疗策略至关重要。在这项研究中，使用25只雄性BALB/c小鼠通过皮下注射HSV-1悬液（100微升，1×PFU/mL）进行了小鼠模型实验。小鼠被分为5组，其中1到3组被指定为干预组，4和5组作为阳性和阴性对照组。病毒接种后2天，小鼠通过皮下注射不同浓度的Herbix进行治疗（100、200和300毫克/毫升）。在实验前后采集小鼠的血液样本（0.5至1毫升），并在三周的随访期后将小鼠处死并取出脾脏进行淋巴细胞分析。我们发现，在300毫克/毫升的剂量下给予Herbix的治疗效果最佳，其特点为延迟皮肤病变的形成，增加存活率和淋巴细胞增殖，上调干扰素α（IFN-α）和肿瘤坏死因子α（TNF-α）基因表达，并增加细胞毒和辅助T淋巴细胞的极化，与对照组相比。这些结果表明，Herbix在300毫克/毫升的剂量下对治疗小鼠疱疹和刺激免疫反应具有显著疗效，成为进一步研究抗疱疹药物的潜在候选者。

Herpes simplex virus-1 (HSV-1) infections can cause significant harm to individuals, including blindness, congenital defects, genital herpes, and even cancer, with no definitive cure .so, finding new treatment strategies is crucial. In this study, 25 male BALB/c mice were used to conduct a mouse model of herpes by subcutaneously injecting an HSV-1 suspension (100 µL of 1×  PFU/mL). The mice were divided into 5 groups with groups 1 to 3 designated as intervention groups, and groups 4 and 5 serving as positive and negative control groups, respectively. After 2 days of virus inoculation, the mice were treated with different concentrations of Herbix (100, 200, and 300 mg/mL) via subcutaneous injection. Mice Blood samples (0.5 to 1 mL) were taken from the mice before and after the experiments, and after three-week follow-up period, the mice were sacrificed and the spleens were removed for lymphocyte analysis. we found that administration of Herbix at a dose of 300 mg/mL showed the greatest efficacy, characterized by a delay in skin lesion formation, an increment in survival rate and lymphocyte proliferation, upregulation of the gene expression of interferon alpha (IFN-α) and tumor necrosis factor alpha (TNF-α), and an increase in the polarization of cytotoxic and helper T lymphocytes compared to the control group. These results suggest that Herbix at a dose of 300 mg/mL is effective in treating murine herpes and stimulating immune responses, making it a potential candidate for further investigation as an antiherpetic drug.